ERT2-Cre-ERT2 Lentivirus (CMV Promoter)

Cat. No.
LVP010156
Unit
4 x 500ul
Price
$212.00
Cat. No. LVP010156
Name ERT2-Cre-ERT2 Lentivirus (CMV Promoter)
Unit 4 x 500ul
Description

ERT2-Cre-ERT2 fusion protein of a tamoxifen-regulated form of Cre recombinase and two estrogen receptor T2 (ERT2) genes. Cre recombinase is a Type I topoisomerase from P1 bacteriophage that catalyzes site-specific recombination of DNA between loxP sites.

This ready-to-use lentivirus is part of abm’s Lentiviral Expression System and can be used to overexpress your gene of interest in a wide range of host cells. Lentiviruses have the ability to integrate into the host genome and generate a stable cell line expressing your gene of interest.

Applications
  • Direct non-viral plasmid transfection for immediate expression
  • Package into Lentiviral particles for high efficiency transduction and stably integrated expression

abm recommends using Cat# G074, Lentifectin™ in conjunction with one of the following packaging mixes. The suggested packaging mix for this vector is Cat# LV003, 2nd Generation Packaging Mix. Alternatively, you can also use Cat# LV053, 3rd Generation Packaging Mix

Titer 107 IU/mL
Storage Condition

Serum-free DMEM with 5% PEG6000

Material Citation If use of this material results in a scientific publication, please cite the material in the following manner: Applied Biological Materials Inc, Cat. No. LVP010156
Print/Download Datasheet
Search CoA here
There are no FAQs for this product yet!
  • Yu, S., Li, Y., Ren, H., Zhou, H., Ning, Q., Chen, X., Hu, T., & Yang, L. (2020). PDK4 promotes tumorigenesis and cisplatin resistance in lung adenocarcinoma via transcriptional regulation of EPAS1. Cancer Chemotherapy and Pharmacology, 87(2), 207–215. https://doi.org/10.1007/s00280-020-04188-9‌
This product has no review yet.